Fang J Y, Lin H H, Hsu L R, Tsai Y H
School of Pharmacy, Chia Nan College of Pharmacy and Science, Tainan Hsien, Taiwan.
Chem Pharm Bull (Tokyo). 1997 Sep;45(9):1504-9. doi: 10.1248/cpb.45.1504.
The necessity for antibacterial agents with greater intracellular efficacy has led to the development of endocytosable drug carriers such as liposomes. Enoxacin was selected as a model drug incorporated in various liposome formulations as a therapeutic dosage form using the ethanol injection method and freeze-drying. Liposomal behavior after preparation and stability test was characterized by determining the physicochemical properties of enoxacin encapsulation percent, vesicle size and turbidity. The non-phospholipid formulation of stratum corneum liposomes showed the highest encapsulation efficiency after preparation among nine liposomal formulations. The addition of dissacharides in liposomes also enhanced the encapsulation of enoxacin due to the protection of phospholipid bilayers during the freeze-drying process. The liposomes with negatively charged component and dissacharides showed lower enoxacin leakage after five weeks of storage at 45 degrees C, suggesting these formulations have high stability in long-term storage. The negative liposomes showed a different behavior than others in their decrease of size and turbidity during storage, possibly due to high surface charges of the negative formulation. Cholesterol stabilized bilayers interacted with plasma and high density lipoprotein (HDL) retained enoxacin in the vesicles. Nevertheless, liposomes with cholesterol caused a hydrolysis problem after incubation with normal saline. The formulation with trehalose not only showed high stability in storage but also in plasma and HDL. This suggested trehalose was useful to incorporate with phospholipids to produce a highly encapsulated and stabilized liposomes of enoxacin. This study also demonstrated that thought is required in utilizing turbidity as a direct index of liposomal vesicle size.
对具有更高细胞内疗效的抗菌剂的需求促使了可内吞药物载体(如脂质体)的发展。选择依诺沙星作为模型药物,采用乙醇注入法和冷冻干燥技术将其制成各种脂质体制剂作为治疗剂型。通过测定依诺沙星的包封率、囊泡大小和浊度等物理化学性质,对制备后的脂质体行为和稳定性进行了表征。角质层脂质体的非磷脂制剂在九种脂质体制剂中制备后显示出最高的包封效率。在脂质体中添加二糖也提高了依诺沙星的包封率,这是因为在冷冻干燥过程中对磷脂双层起到了保护作用。含有带负电荷成分和二糖的脂质体在45℃储存五周后依诺沙星泄漏率较低,表明这些制剂在长期储存中具有高稳定性。带负电荷的脂质体在储存过程中尺寸和浊度的下降表现与其他脂质体不同,这可能是由于其高表面电荷所致。胆固醇稳定的双层与血浆相互作用,高密度脂蛋白(HDL)将依诺沙星保留在囊泡中。然而,含胆固醇的脂质体与生理盐水孵育后会产生水解问题。含海藻糖的制剂不仅在储存中表现出高稳定性,在血浆和HDL中也是如此。这表明海藻糖与磷脂结合有助于制备高包封率和高稳定性的依诺沙星脂质体。本研究还表明,在将浊度用作脂质体囊泡大小的直接指标时需要谨慎考虑。